linjc16/ctgov huggingface dataset:
Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI

Study Overview
=================
Brief Summary
-----------------
Retrospectively investigating the effect of DM on response rate and outcomes during immunotherapy treatment in patients with NSCLC in the last 5 years.

Detailed Description
-----------------
Lung cancer continues to be the most common cause of cancer-related death worldwide for both males and females despite the identification of clinically-actionable driver mutations in genomic subgroups of patients. Non-small cell lung cancer (NSCLC) is the most common histological diagnosis for 85% of lung cancer patients. Immune checkpoint inhibitors (ICI) has significantly altered the prognosis for patients with advanced non-small cell lung cancer (mNSCLC) as it has been shown to have distinct and long-lasting impacts on survival in first and second line treatment. As a result, immunotherapy has emerged as the backbone of care for people with NSCLC. Although some patients benefit considerably from ICI, not all patients do. A comprehensive research effort exists to identify and characterize variables that could predict or boost the response to ICI. At the same time, diabetes mellitus (DM) is becoming more prevalent globally and lung cancer patients frequently suffer from a variety of comorbidities, including (DM). However, its effect on treatment outcomes is still unclear, particularly in the era of immunotherapy.

Official Title
-----------------
Effect of Diabetes Mellitus on Outcomes and Response Rate in Patients With Advanced NSCLC on Immunotherapy

Conditions
-----------------
Diabetes Mellitus, Non Small Cell Lung Cancer Metastatic

Intervention / Treatment
-----------------
* Combination Product: Pembrolizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All consecutive patients with advanced Non Small Cell Lung Cancer who received Immune Check Inhibitors alone or in combination with chemotherapy, either as first line or as a subsequent line Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Combination Product: Pembrolizumab|Immune check inhibitor with OHA|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response Rate | CT evaluation for response rate measured by RECIST criteria | 12 weeks after starting immunotherapy regimen. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NSCLC, DM, ICI, OHA
Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study was to assess the appropriateness of antiviral therapy with nirmatrelvir-ritonavir in hospitalized patients.

Official Title
-----------------
Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients: a Multicenter Retrospective Study in China

Conditions
-----------------
Hospitalized Patients

Intervention / Treatment
-----------------
* Drug: Nirmatrelvir-Ritonavir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hospitalized patients receiving at least one dose nirmatrelvir-ritonavir Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Nirmatrelvir-Ritonavir<br>Hospitalized patients receiving at least one dose Nirmatrelvir-Ritonavir | Drug: Nirmatrelvir-Ritonavir<br>* Nirmatrelvir-Ritonavir<br>* Other names: PAXLOVID;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The prevalence of inappropriate use of nirmatrelvir-ritonavir | Four aspects were evaluated to identify the rationality of prescribing NMVr, including indication, administration (dose, timing, and duration), contraindications, and drug-drug interactions. | baseline |
Comparison of Analgesic Efficacy of PENB Block With FICB in Post Operative Hip Fracture Patients

Study Overview
=================
Brief Summary
-----------------
This study was done to evaluate two different interventions for postoperative pain control in patients undergoing hip surgeries. Fifty patients, divided in two equal groups, were included in the study. Patients in Group P were given pericapsular nerve group (PENG) block while those in Group F were given fascia iliaca compartment block (FICB). Pain score, using Numeric Rating scale as a measurement tool, was assessed at one, six, eighteen and twenty fours after the procedure as a primary outcome. Total tramadol consumption in milligrams was recorded as a secondary outcome.

Official Title
-----------------
Comparison of Analgesic Efficacy of Ultrasound Guided Pericapsular Nerve Group Block Versus Fascia Iliaca Compartment Block in Patients of Hip Fracture

Conditions
-----------------
Post-operative Pain Management, Hip Fracture Surgery

Intervention / Treatment
-----------------
* Drug: PENG block
* Drug: FICB Block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: surgical correction of fracture neck of femur under spinal anaesthesia Exclusion Criteria: allergy to local anaesthetics bleeding disorders morbid obesity with BMI more than 35 patients of chronic pain drug addiction psychiatric issues

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PENG Block Group<br> | Drug: PENG block<br>* 10ml of 0.125% isobaric bupivacaine injected<br>|
| Experimental: FICB Group<br> | Drug: FICB Block<br>* 20ml of 0.125% isobaric bupivacaine injected<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain score using Numeric Rating scale | Pain scored assessed after completion of surgery at one, six, eighteen and twenty fours | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total Tramadol consumption | Total Tramadol consumption In twenty four hours | 24 hours |
Troponin to Detect Major Cardiovasculaire Advserse Events on Immune Checkpoint Inhibitors

Study Overview
=================
Brief Summary
-----------------
Recent guidelines suggest the use of troponin to detect immnune related cardiovascular advserse events in patients treated by immune checkpoint inhibitors for cancer. However, there is no proof that patients on immune checkpoint inhibitors benefit from this active surveillance strategy. The suspicion of cardiovascular events may lead to the interruption of cancer therapies. The TILT study aims at assessing: (i) the efficiency of troponin measurments in asymptomatic patients to prevent the further advent of major cardiovascular events; (ii) its safety in terms of cancer therapy completion.

Detailed Description
-----------------
Retrospective two-center study comparing two groups of patients on immune checkpoint inhibitors: Group 1: active surveillance by serial troponin measures not prompted by cardiovascular symptoms ; Group 2: no troponin measures. For any solid cancer or stage.

Official Title
-----------------
Troponin to Detect Major Cardiovasculaire Advserse Events on Immune: a Case Control Retrospective Study

Conditions
-----------------
Cancer, Immune Checkpoint Inhibitor, Cardiovascular Biomarkers

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All solid cancer patients treated by immune checkpoint inhibitors 2017-2022 Exclusion Criteria: Patients enrolled in an invterventional study (e.g., pharma trial)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active surveillance by means of troponin measurements<br> | Other: No intervention<br>* No intervention<br>|
| No active surveillance by means of troponin measurements<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major cardiovascular event | Acute coronary syndrome, stroke, myocarditis, heart failure, sustained ventricular arrhymias, cardiovascular death | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Completion of cancer therapy as scheduled | Cardiovascular contre indication to immune checkpoint inhibitors | 5 years |
The Impact of Conventional Hemodialysis and Renal Transplantation on the Global Longitudinal Strain of the Left Ventricle

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate a group of patients with chronic kidney disease in stages 3-5 by conventional 2D echocardiography, tissue Doppler techniques and speckle tracking - LV GLS and determine the correlation of ultrasound parameters with mortality. Additionally, fibrosis-related biomarkers will be studied in this population.

Official Title
-----------------
The Impact of Conventional Hemodialysis and Renal Transplantation on the Global Longitudinal Strain of the Left Ventricle

Conditions
-----------------
Cardiovascular Diseases, Chronic Kidney Diseases, Fibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: eGFR < 15 ml/min/1.73m2 (CKD - EPI) NYHA class I-II Hemodynamic stability Exclusion Criteria: age < 18 years old poor acoustic window atrial fibrillation recent Acute Myocardial Infarction pacemaker

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Variation of GLS |  | 3 years | 
| All-cause mortality |  | 3 years |
Vitreous Hyper Reflective Dots in Association With Pseudophakic Cystoid Macular Edema

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess the association between vitreous hyper-reflective dots (VHD) and the macular thickness changes following uneventful phacoemulsification. In this prospective study the investigators performed optical coherence tomography (OCT) imaging in patients undergoing cataract surgery preoperatively and postoperatively after 1 week, 1 month and 3 months and analyzed the OCTs for VHDs. The investigators then measured the macular thickness in patients with VHDs and without VHDs and correlated the macular thickness with the number of VHDs.

Official Title
-----------------
Prospective Analysis of the Correlation Between Hyperreflective Dots in the Vitreous Body and the Appearance of a Pseudophakic Cystoid Macular Edema

Conditions
-----------------
Cystoid Macular Edema Following Cataract Surgery, Vitreous Hyperreflective Dots

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing cataract surgery minimum age 18 years phacoemulsification technique subsequent implantation of a monofocal hydrophobic acrylic intraocular lens Exclusion Criteria: intraoperative complications including capsule rupture with or without anterior vitrectomy iris bites previous interventions including vitrectomy glaucoma surgery exudative or dry age-related macular degeneration presence of diabetes history or presence of retinal vein occlusion or uveitis epiretinal glioses

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| vitreous hyperreflective dots | Change of correlation between occurrence of vitreous hyperreflective dots and the macular thickness | preoperatively until 3 months postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
VHD, phacoemulsification, CME
Relmacabtagene Autoleucel in Patients With LBCL

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy and safety of Relmacabtagene autoleucel for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) in real-world

Detailed Description
-----------------
The purpose of this study is to collect efficacy and safety data over a 6-month period following treatment of adult patients with r/r LBCL with Relmacabtagene autoleucel. The treating physicians in the study will determine the most appropriate diagnostic and therapeutic regimen for their patients based on clinical practice.There will be no therapeutic intervention as a result of this study. There will be no subgroups of any kind in this study, and subgroup analyses will be performed based on the actual data collected during the analysis.

Official Title
-----------------
A Real World Study of Treatment of Relmacabtagene Autoleucel in Relapsed or Refractory Large B-Cell Lymphoma

Conditions
-----------------
Large B-cell Lymphoma

Intervention / Treatment
-----------------
* Biological: Relmacabtagene Autoleucel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with established r/r LBCL; Patients already treated with commercially available Relmacabtagene Autoleucel Exclusion Criteria: No

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Relmacabtagene Autoleucel<br>Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day1. | Biological: Relmacabtagene Autoleucel<br>* A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells<br>* Other names: JWCAR029;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ORR | Percentage of participants with CR or PR | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CRR | Complete response rate | 6 months | 
| DOR | Duration of response | 6 months | 
| Progression-Free Survival (PFS) | PFS is defined as the time from the Relmacabtagene Autoleucel infusion date to the date of disease progression per Lugano classification or death from any cause. | 6 months | 
| Overall Survival (OS) | OS is defined as the time from Relmacabtagene Autoleucel infusion to the date of death from any cause. | 6 months | 
| Adverse events (AEs) | Types, frequency, and severity of adverse events and laboratory anomalies Physiological parameter | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Relmacabtagene Autoleucel, Chimeric antigen receptor T cells
Pre-implantation Genetic Testing for Monogenic Disease: Single Center Experience

Study Overview
=================
Brief Summary
-----------------
This monocentric retrospective observational study aims to evaluate the efficacy of pre-implantation genetic testing for monogenic diseases (PGT-M). The effectiveness will be assessed in terms of live birth rate (LBR), cumulative live birth rate (CLBR) per couple, and abortion rate (AR). Considering how many cycles the participants have undergone to achieve a viable blastocyst. The secondary objective is to evaluate the incidence of aneuploidy in unaffected embryos, in order to understand the need for pre-implantation genetic testing for aneuploidy (PGT-A)in addition to PGT-M.

Official Title
-----------------
Pre-implantation Genetic Testing for Monogenic Disease: Single Center Experience

Conditions
-----------------
Genetic Disease, Aneuploidy

Intervention / Treatment
-----------------
* Genetic: Pre-implantation genetic testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients fertile or infertile that have undergone preimplantation genetic testing for monogenic diseases (PGTM). Exclusion Criteria: No exclusion criteria will be taken into consideration.

Ages Eligible for Study
-----------------
Minimum Age: 34 Years
Maximum Age: 42 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: Pre-implantation genetic testing|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Live birth rate (LBR) | LBR will be measured as a percentage | 7 years of inclusion | 
| Cumulative live birth rate (CLBR) per couple | CLBR per couple will be measured as a percentage | 7 years of inclusion | 
| Abortion rate (AR) | AR will be measured as a percentage | 7 years of inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aneuploidy | Aneuploidy embryo rate will be measured as a percentage | 7 years of inclusion |
Sodiumhexametaphosphate as Pulp Capping Material for Primary Teeth

Study Overview
=================
Brief Summary
-----------------
Sodiumhexametaphosphate will be tested as pulp capping material in comparison to MTA for primary teeth pulp therapy

Official Title
-----------------
Sodiumhexametaphosphate Versus MTA as Pulp Capping Material for Primary Teeth ( Randomized Clinical Trial)

Conditions
-----------------
Pulp Disease, Dental

Intervention / Treatment
-----------------
* Other: Pulp therapy
* Drug: Sodiumhexametaphosphate
* Other: MTA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: physical healthy children cooperative children primary molar with deep carious lesion absence of pain or transient momentary pain Exclusion Criteria: Uncooperative children children with systemic disorders periapical lesions sever pain

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sodiumhexametaphosphate<br> | Other: Pulp therapy<br>* Pulp capping material<br>Drug: Sodiumhexametaphosphate<br>* Sodiumhexametaphosphate<br>|
| Active Comparator: MTA<br> | Other: Pulp therapy<br>* Pulp capping material<br>Other: MTA<br>* MTA<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical success | Absence of pain, swelling and sinus tract | One year | 
| Radiographic success | Absence of periapical lesions, internal or external root resorption | One year |
A Registry Study of Biomarkers in Ischemic Heart Disease ( BIOMS-IHD )

Study Overview
=================
Brief Summary
-----------------
The registry study aims to discover biomarkers for accurate classification and risk assessment of ischemic heart disease.

Detailed Description
-----------------
The purpose of this study is to discover biomarkers for early identification, diagnosis, molecular classification, and intervention based on the mechanism of ischemic heart disease（IHD）. Using mass spectrometry-based metabolomics and multimodal imaging technology, the study aims to further construct a new system for early risk stratification of IHD based on abnormal metabolites.

Official Title
-----------------
A Registry Study of Biomarkers in Ischemic Heart Disease ( BIOMS-IHD )

Conditions
-----------------
Cardiovascular Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria : Aged 18 years or older. Previous ischemic symptoms/signs or electrocardiographic ischemic changes and. >70% stenosis of at least one epicardial coronary artery on angiography or a history of myocardial infarction or coronary revascularization. Exclusion Criteria: Patients with acute myocardial infarction were excluded from the study. Current known inability to follow instructions or comply with follow-up procedures. Eligible patients without informed consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of hospitalizations for acute heart failure (HF) | Unplanned emergency visits or hospitalizations leading to HF deterioration were defined as hospitalizations for HF | These data is collected during follow-up visit at 3/6/12/24/36/48 months after discharge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiovascular events (MACE) | Major adverse cardiovascular events (MACE) in overall population, defined as composite of all-cause death, Heart Failure hospitalization, recurrent myocardial infarction, stroke or ischemia-driven revascularization. | These data is collected during follow-up visit at 3/6/12/24/36/48 months after discharge | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ischemic heart disease